Effective delivery of large genes to the retina by dual AAV vectors
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Retinal gene therapy with adeno‐associated viral (AAV) vectors is safe and effective in humans. However, AAV's limited cargo capacity prevents its application to therapies of inherited retinal diseases due to mutations of genes over 5 kb, like Stargardt's disease (STGD) and Usher syndrome type IB (USH1B). Previous methods based on ‘forced’ packaging of large genes into AAV capsids may not be easily translated to the clinic due to the generation of genomes of heterogeneous size which raise safety concerns. Taking advantage of AAV's ability to concatemerize, we generated dual AAV vectors which reconstitute a large gene by either splicing (trans‐splicing), homologous recombination (overlapping), or a combination of the two (hybrid). We found that dual trans‐splicing and hybrid vectors transduce efficiently mouse and pig photoreceptors to levels that, albeit lower than those achieved with a single AAV, resulted in significant improvement of the retinal phenotype of mouse models of STGD and USH1B. Thus, dual AAV trans‐splicing or hybrid vectors are an attractive strategy for gene therapy of retinal diseases that require delivery of large genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even though vector reconstitution in the retina has been detected for clinically relevant large transgenes, such as ABCA4 or MYO7A, due to lack of proper controls (e.g., using oversized monocistronic vectors) and accurate protein quantification methods, determining parameters for clinical approaches has been lacking (Dyka et al., 2014; Trapani et al., 2014, 2015).”
From Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting (2017) · cites this paper as Trapani et al., 2014
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is worth remembering that the multiplicity of infection is about 10 4 - 10 5 vector particles at the level of the RPE, depending on the disease state at the time of treatment (Trapani et al., 2014; Ramachandran et al., 2017).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Trapani et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“advances in dual and triple AAV vectors with enhanced cargo capacity now allow for the delivery of larger genes [242], including anti-VEGF and complement regulatory molecules”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [242]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The hybrid dual AAV strategy was initially proposed by Gosh and colleagues in 2008 [54] and found to significantly improve transgene reassembly in a variety of studies thereafter [29,49].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In their study, Trapani et al. demonstrated that in vitro transduction with vectors with oversized genomes did not result in efficient transgene expression. 46”
From Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids (2016) · cites this paper as [46]
Experimental — accuracy not yet measured
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305 · cited 1×
“…lipo-fuscin granules (Fig 5D) are expressed as discrete numbers, these were analyzed by deviance from a Negative Binomial generalized linear models (Venables & Ripley, 2002) WT versus Abca4 (cid:1) / (cid:1) neg P = 0.016; WT versus Abca4 (cid:1) / (cid:1) AK-ABCA4 P = 0.03; Abca4 (cid:1) /…”
InfluentialThe Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
A monomeric red fluorescent protein
Campbell, R. E., Tour, O., Palmer, A. E., Steinbach, P. A., Baird, G. S., Zacharias, D. A., & Tsien, R. Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082243699 · Cited by 2,365 · cited 1×
“The membrane was then analyzed by X-ray autoradiography using Amersham Hyperfilm TM MP (GE Healthcare Europe, GmbH).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“…gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and requiring a…”
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“While AAV-mediated gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and…”
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 4×
“Although the Abca4 (cid:1) / (cid:1) mouse model does not undergo severe PR degeneration (Wu et al , 2010a), the absence of the ABCA4-encoded all-trans retinal transporter in PR outer segments (Illing et al , 1997; Sun & Nathans, 1997) causes an accumulation of lipo-fuscin in PR as well as in RPE,…”
InfluentialWeng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 5×
“ABCA4 and MYO7A expression was normalized to Filamin A or Dysferlin for the in vitro and in vivo experiments, respectively.”
InfluentialMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 2×
“…gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and requiring a…”
Self-citation
Cited by
Items 101–200 of 284
Correction of Monogenic and Common Retinal Disorders with Gene Therapy
Sengillo, J., Justus, S., Cabral, T., & Tsang, S. (2017) · Genes · doi:10.3390/genes8020053 · Cited by 37
“Encouragingly, co-infected cells showed recombination of the two halves, leading to a full-length gene product [84,85].”
BackgroundDual-AAV delivery of large gene sequences to the inner ear
Reisinger, E. (2020) · Hearing Research · doi:10.1016/j.heares.2019.107857 · Cited by 37
Hair cell-specific Myo15 promoter-mediated gene therapy rescues hearing in DFNB9 mouse model
Wang, H., Xun, M., Tang, H., Zhao, J., Hu, S., Zhang, L., Lv, J., Wang, D., Chen, Y., Liu, J., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102135 · Cited by 37
Efficient Production of Dual Recombinant Adeno-Associated Viral Vectors for Factor VIII Delivery
Wang, Q., Dong, B., Firrman, J., Roberts, S., Moore, A. R., Cao, W., Diao, Y., Kapranov, P., Xu, R., & Xiao, W. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2014.093 · Cited by 35
Tuohy, G., & Megaw, R. D. (2021) · Biomolecules · doi:10.3390/biom11050760 · Cited by 34
A Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome
French, L. S., Mellough, C., Chen, F. K., & Carvalho, L. S. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00183 · Cited by 36
Revolution in Gene Medicine Therapy and Genome Surgery
Jiang, D. J., Xu, C. L., & Tsang, S. H. (2018) · Genes · doi:10.3390/genes9120575 · Cited by 35
“This technique utilizes the inherent ability of AAV genomes to concatemerize, and once inside the cell, the reconstitution of the full length gene is achieved upon co-infection of the same cell [60].”
MethodViral vectors for gene delivery to the inner ear
Maguire, C. A., & Corey, D. P. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107927 · Cited by 34
PCDH15 dual-AAV gene therapy for deafness and blindness in Usher syndrome type 1F models
Ivanchenko, M. V., Hathaway, D. M., Mulhall, E. M., Booth, K. T. A., Wang, M., Peters, C. W., Klein, A. J., Chen, X., Li, Y., György, B., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177700 · Cited by 33
“Vector 1 (AAV-Pcdh15 5′) included a CMV promoter, the N-terminal half of the Pcdh15 coding sequence, and a splice donor (SD) site followed by a highly recombinogenic sequence from F1 phage (AK) (32).”
Research Models and Gene Augmentation Therapy for CRB1 Retinal Dystrophies
Boon, N., Wijnholds, J., & Pellissier, L. P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00860 · Cited by 36
Ferla, R., Dell’Aquila, F., Doria, M., Ferraiuolo, M. A., Noto, A., Grazioli, F., Ammendola, V., Testa, F., Melillo, P., Iodice, C., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.002 · Cited by 32
“://creativecommons.org/licenses/by-nc-nd/4.0/). results in the reconstitution and expression of full-length human MYO7A in both mice and pigs9,10 and improves the retinal defects of the shaker1 (sh1) mouse model of USH1B.9 Our aim is to translate retinal gene therapy with dual AAV8.”
BackgroundMethodInfluentialSelf-citationDual AAV Vectors for Stargardt Disease
Trapani, I. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_11 · Cited by 33
Self-citationGene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A
Lopes, V. S., & Williams, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017319 · Cited by 35
“Western blot analysis of posterior eye segments from treated Myo7a mice showed that the trans-splicing and AK hybrid AAV dual vectors resulted in only 20% of the MYO7A level found in heterozygous littermates, and correction of a photoreceptor phenotype could not be determined (Trapani et al. 2014).”
BackgroundMethodResultInfluentialGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“27,28 AAV has been used in numerous clinical trials, including early trials for RPE65 29–31 (Table 2).”
Lau, S. C., Grati, M., Isgrig, K. T., Sinan, M., Calabro, K. R., Zhu, J., Ishibashi, Y., Ozgur, Z., Wafa, T. T., Belyantseva, I. A., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.012 · Cited by 31
“In addition, sub-retinal injection of the hybrid dual-AAV vectors carrying human MYO7A cDNA into a Myo7a mutant mouse (shaker-1, Myo7a) resulted in expression of full-length human MYO7A and improvement of melanosome and rhodopsin localization in the mouse retina.(14)”
BackgroundMethodInfluentialSpliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA
Dooley, S. J., McDougald, D. S., Fisher, K. J., Bennicelli, J. L., Mitchell, L. G., & Bennett, J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.014 · Cited by 32
“reading frame.(13) The limitations of this approach concern (1) efficiency—vectors of each genome must transduce the same cell and further, the genomes must recombine or undergo concatamerization in the proper orientation, and (2) potential immunogenicity—both fragments have the potential to produce partial gene produ…”
BackgroundNathwani, A. C., McIntosh, J., & Sheridan, R. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.169 · Cited by 31
“14 Infection with wild-type AAV does result in long-term persistence of neutralizing anti-AAV antibodies, with AAV2 showing the highest seroprevalence, with antibody titers varying geographically and with age.”
A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration
Santiago, C. P., Keuthan, C. J., Boye, S. L., Boye, S. L., Imam, A. A., & Ash, J. D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.016 · Cited by 31
Panagiotopoulos, A.-L., Karguth, N., Pavlou, M., Böhm, S., Gasparoni, G., Walter, J., Graf, A., Blum, H., Biel, M., Riedmayr, L. M., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.036 · Cited by 30
Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025) · Cell Proliferation · doi:10.1111/cpr.13808 · Cited by 33
“The strategy relies on the recombination of two AAV vectors within cells to form a complete gene-editing tool [138].”
Recent Therapeutic Progress and Future Perspectives for the Treatment of Hearing Loss
Lye, J., Delaney, D. S., Leith, F. K., Sardesai, V. S., McLenachan, S., Chen, F. K., Atlas, M. D., & Wong, E. Y. M. (2023) · Biomedicines · doi:10.3390/biomedicines11123347 · Cited by 30
“The AAV delivery of full-length MYO7A cDNA has been shown to be effective in vivo and in vitro and resulted in wild-type levels of expression [63–66].”
Usher syndrome: a review of the clinical phenotype, genes and therapeutic strategies
Toms, M., Bitner-Glindzicz, M. A. K., Webster, A. R., & Moosajee, M. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1033403 · Cited by 31
“However, restoration of protein expression levels and phenotypic rescue has been reported to be less effective when using this approach [158,159,162].”
BackgroundThe Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease
Velazquez, L. A. M., & Ballios, B. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111542 · Cited by 28
“…have effectively used this split vector approach in preclinical models: first for the delivery of the erythropoietin genomic locus [115], but later for retinal disease genes caused by variants in the MYO7A gene (Usher syndrome, type 1B) [116,117] and the ABCA4 gene (Stargardt disease) [117].”
MethodPotential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
“In the additional paper, siRNAs targeting either VEGF, VEGFR-1, VEGFR-2, or a mix of the three were displayed to reduce neovascularisation, herpes simplex virus-induced angiogenesis as well as against lesions of stromal keratitis [324].”
BackgroundFetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction
Hastings, M. L., & Brigande, J. V. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107931 · Cited by 27
Chen, K.-S., Chan, H.-C., & Chan, C.-M. (2025) · Drugs · doi:10.1007/s40265-025-02237-2 · Cited by 27
“Recent advancements have enabled MYO7A gene delivery in patients with Usher syndrome type 1B, potentially overcoming gene size constraints [117].”
Ryu, J., Statz, J. P., Chan, W. K., Burch, F. C., Brigande, J. V., Kempton, B., Porsov, E. V., Renner, L. M., McGill, T., Burwitz, B. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13689-x · Cited by 27
Pluripotent stem cells and their utility in treating photoreceptor degenerations
Aghaizu, N. D., Kruczek, K., Gonzalez-Cordero, A., Ali, R. R., & Pearson, R. A. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2017.01.001 · Cited by 27
Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application
Yin, L., He, H., Zhang, H., Shang, Y., Fu, C., Wu, S., & Jin, T. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70447 · Cited by 27
“…Vivo. vector approach is widely used in transferring either β ‐ galactosidase or minidystrophin to skeletal muscle following both intramuscular and intravenous injection, as well as transferring eye ‐ disease – related genes, MYO7A or ABCA4, to the retina following subretinal injection [66 – 69].”
Cav1.4 dysfunction and congenital stationary night blindness type 2
Koschak, A., Fernández‐Quintero, M. L., Heigl, T., Ruzza, M. R. D., Seitter, H., & Zanetti, L. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02570-x · Cited by 27
Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases
Hansen, S., McClements, M. E., Corydon, T. J., & MacLaren, R. E. (2023) · Cells · doi:10.3390/cells12030440 · Cited by 25
“Additionally, suboptimal splice-sites may lead to imperfect structure after re-assembly of the full-length PE or unwanted/truncated transgene constructs [43,91,96,101,116].”
BackgroundThe new landscape of retinal gene therapy
Ku, C. A., & Pennesi, M. E. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31842 · Cited by 26
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“…and demonstrates best-in-class transduction rates of retinal cells, it is worth remembering that the multiplicity of infection is about 10 4 - 10 5 vector particles at the level of the RPE, depending on the disease state at the time of treatment (Trapani et al., 2014; Ramachandran et al., 2017).”
Successful large gene augmentation of USH2A with non-viral episomal vectors
Toms, M., Toualbi, L., Almeida, P. V., Harbottle, R. P., & Moosajee, M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.012 · Cited by 23
Ocular gene therapy for choroideremia: clinical trials and future perspectives
Xue, K., & MacLaren, R. E. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1475232 · Cited by 24
Gene Therapy to the Retina and the Cochlea
Crane, R., Conley, S. M., Al‐Ubaidi, M. R., & Naash, M. I. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.652215 · Cited by 25
Abbasi, M., Aghamollaei, H., Vaez, A., Amani, A. M., Kamyab, H., Chelliapan, S., Jamalpour, S., & Zambrano-Dávila, R. (2025) · The Ocular Surface · doi:10.1016/j.jtos.2025.03.004 · Cited by 23
Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease
Wang, L., Shah, S. M., Mangwani‐Mordani, S., & Gregori, N. Z. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196229 · Cited by 23
“Pre-clinical studies have shown early signs of success in delivering full-length ABCA4 coding regions using dual AAV and trans-splicing techniques (Figure 2) [28,29].”
In vivo liver targeted genome editing as therapeutic approach: progresses and challenges
Simoni, C., Barbon, E., Muro, A. F., & Cantore, A. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1458037 · Cited by 23
In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
Doisne, N., Grauso, M., Mougenot, N., Clergue, M., Souil, C., Coulombe, A., Guicheney, P., & Neyroud, N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.661413 · Cited by 23
Split AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1)
Li, R., Jing, Q., She, K., Wang, Q., Jin, X., Zhao, Q., Su, J., Song, L., Fu, J., Wu, X., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.017 · Cited by 21
“15,37 Overlap, hybrid, and transplicing are three popular options to produce ABCA4 dual vector systems, while the levels of full-length ABCA4 detected by western blot in eye tissue of ABCA4-KO mice treated with optimized overlapping dual vector were 1% of the ABCA4 levels detected in eyes of WT…”
CRISPR Technology for Ocular Angiogenesis
Chung, S. H., Sin, T.-N., Ngo, T., & Yiu, G. C. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.594984 · Cited by 21
“Interestingly, although some reports suggest that co-delivery of two AAV vectors may be less efficient than a single AAV (Trapani et al., 2014), our group found that dual AAV8 delivery of SpCas9 and gRNAs resulted in higher on-target editing rates in vivo, greater VEGF protein reduction, and more effective CNV suppres…”
BackgroundAssessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy
Albini, S., Palmieri, L., Dubois, A., Bourg, N., Lostal, W., & Richard, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411421 · Cited by 21
Urîtu, C. M., Călin, M., Maier, S. S., Cojocaru, C., Nicolescu, A. F., Peptanariu, D., Constantinescu, C. A., Stan, D. L., Bãrboiu, M., & Pinteală, M. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01342a · Cited by 21
Huang, J., Li, J., Xu, X., & Li, K. (2025) · Biomolecules · doi:10.3390/biom15070940 · Cited by 21
“These findings underscore the clinical potential of protein-level approaches in overcoming AAV’s packaging constraints [109,110].”
Ferreira, M. V., Fernandes, S., Almeida, A. I., Neto, S., Mendes, J. P., Silva, R. J. S., Peixoto, C., & Coroadinha, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310524 · Cited by 22
“The majority of dual-AAV vector strategies are based on DNA trans-splicing mechanisms such as ITR concatemerization or homologous recombination [4,5].”
BackgroundThe ABCs of Stargardt disease: the latest advances in precision medicine
Zaydon, Y. A., & Tsang, S. H. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01272-y · Cited by 20
“If the gene cannot fit into a single AAV vector, scientists split it into halves ( 5 kb in size) [45].”
BackgroundDelivering large genes using adeno-associated virus and the CRE-lox DNA recombination system
Datta, P., Rhee, K.-D., Staudt, R. J., Thompson, J. M., Hsu, Y., Hassan, S., Drack, A. V., & Seo, S. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae144 · Cited by 20
Corydon, T. J., & Bek, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101323 · Cited by 20
Antiangiogenic Eye Gene Therapy
Corydon, T. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.064 · Cited by 21
“28 In the case of the tyrosine variants, enhanced intracellular traffick-ing is obtained—and hence increased transduction efficacy—by the mutation of surface-exposed tyrosine residues on the capsid, thereby rendering the internalized virus particles less sensitive to proteasome-mediated degradation…”
Nitzahn, M., Allegri, G., Khoja, S., Truong, B., Makris, G., Häberle, J., & Lipshutz, G. S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.011 · Cited by 21
“Together these issues would typically be expected to result in expression that is lower than that achieved by single AAV vectors.(22,35,36) While it would likely be more efficacious if a single hcoCPS1 cDNA vector could be made, previous unpublished attempts by our lab to generate single AAV vectors expressing CPS1 we…”
ResultCombining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing
Epstein, B. E., & Schaffer, D. V. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_2 · Cited by 21
Gene therapy approaches for prevention of retinal degeneration in Usher syndrome
Williams, D. S., Chadha, A., Hazim, R. A., & Gibbs, D. (2017) · Gene Therapy · doi:10.1038/gt.2016.81 · Cited by 21
CRISPR Systems Suitable for Single AAV Vector Delivery
Stevanovic, M., Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Current Gene Therapy · doi:10.2174/1566523221666211006120355 · Cited by 19
Assessment of AAV Dual Vector Safety in the Abca4−/− Mouse Model of Stargardt Disease
McClements, M. E., Barnard, A. R., Charbel Issa, P., & MacLaren, R. E. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.20 · Cited by 18
Dual AAV vectors for efficient delivery of large transgenes
Mittas, D. M., Riedmayr, L. M., Gavrilov, Z., Weber, V. J., Otify, D. Y., Mehlfeld, V., Szalontai, B., Ucambarlic, E., Gandor, C. L. A., Heigl, T., et al. (2025) · Nature Protocols · doi:10.1038/s41596-025-01243-8 · Cited by 20
The rise of cochlear gene therapy
Landegger, L. D., Reisinger, E., Lallemend, F., Hage, S. R., Grimm, D., & Cederroth, C. R. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.012 · Cited by 21
Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Panikker, P., Roy, S., Ghosh, A., Poornachandra, B., & Ghosh, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906482 · Cited by 19
“7 Kb is separated and packaged into two AAV vectors for later reconstitution within the target cell (153).”
BackgroundMaddalena, A., Dell'Aquila, F., Giovannelli, P., Tiberi, P., Wanderlingh, L. G., Montefusco, S., Tornabene, P., Iodice, C., Visconte, F., Carissimo, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.220 · Cited by 16
“26 In the same study, it was observed that the transduction efficiency of dual AAV hybrid vectors is 6% and 40% of that of a single AAV vector in mice and pigs, respectively.”
InfluentialSelf-citationKosaka, M., Sajiki, A. F., Fujita, K., Yamada, K., Kawano, K., Hirazawa, K., Matsuno, T., Takada, M., Shimozawa, N., Inoue, K., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101474 · Cited by 17
Retinal Ciliopathies and Potential Gene Therapies: A Focus on Human iPSC-Derived Organoid Models
McDonald, A. J., & Wijnholds, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052887 · Cited by 19
“Dual trans-splicing vectors have been used to achieve expression of ABCA4 (6.8 kb) and myosin VIIA (6.6 kb) in both mice and pigs [132].”
MethodInfluentialRetinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
“The low levels of homologous recombination that occurs in post-mitotic neurons, such as photoreceptors, decrease the efficiency of overlapping vectors significantly [77].”
BackgroundMethodInfluentialLiver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Fakhiri, J., Landegger, L. D., & Grimm, D. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108092 · Cited by 15
Retinal Gene Therapy for Usher Syndrome: Current Developments, Challenges, and Perspectives
Dinculescu, A., Link, B. A., & Saperstein, D. A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000378 · Cited by 15
Pasquini, G., Cora, V., Swiersy, A., Achberger, K., Antkowiak, L., Müller, B., Wimmer, T., Fraschka, S. A. K., Casadei, N., Ueffing, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041380 · Cited by 16
Chuang, K., Ma, F., & Priore, L. V. D. (2017) · PubMed Central · Cited by 24
Gilmore, W. B., Hultgren, N. W., Chadha, A., Barocio, S. B., Zhang, J., Kutsyr, O., Flores‐Bellver, M., Canto-Soler, M. V., & Williams, D. S. (2023) · Vision Research · doi:10.1016/j.visres.2023.108311 · Cited by 13
Wu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 17
McClements, M. E., Charbel Issa, P., Blouin, V., & MacLaren, R. E. (2016) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000311 · Cited by 13
Developing New Vectors for Retinal Gene Therapy
Zin, E. A., Öztürk, B. E., Dalkara, D., & Byrne, L. C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041291 · Cited by 14
Gene therapy for epilepsy: An emerging, promising approach for a serious neurological disorder
Ledri, M., & Kokaia, M. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70059 · Cited by 9
“…9 kb. Strategies to address AAV’s packaging constraints include the development of compact genetic payloads, such as miRNA and gene fragments, as well as dual-vector systems, where complementary AAVs deliver separate components of a larger therapeutic gene to achieve functional expression [16, 17].”
Gene therapies for inherited retinal disorders
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Mansergh, F. C., & Palfi, A. (2014) · Visual Neuroscience · doi:10.1017/s0952523814000133 · Cited by 14
“2 ; Trapani et al., 2013 ; Palfi et al., 2012 ).”
BackgroundResultInfluentialSelf-citationClinical applications of retinal gene therapies
Fu, X., Huu, V. A. N., Duan, Y., Kermany, D., Valentim, C. C. S., Zhang, R., Zhu, J., Zhang, C. L., Sun, X., & Zhang, K. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby004 · Cited by 13
“Later, a dual AVV trans-splicing strategy that efficiently reconstituted ABCA4 gene in mice was used and demonstrated significant phenotype improvement.(96) Moreover, lentivirus was also used to infect photoreceptors in Abca4 mice, which showed better results than AAV-based methods when subretinal injections of the ve…”
MethodPiotter, E., McClements, M. E., & MacLaren, R. E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.814131 · Cited by 12
“To overcome this, multiple alternative approaches have been tested, such as a dual vector approach (Trapani et al., 2014; Trapani et al., 2015; McClements et al., 2019), lentiviral vector delivery (Binley et al.”
MethodMajor, L., McClements, M. E., & MacLaren, R. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087603 · Cited by 12
“Dual vector packaging of prime editors is possible with truncated reverse transcriptase variants, however, split plasmid approaches lower activity [35,40,73].”
BackgroundGene editing technology: Towards precision medicine in inherited retinal diseases
Ballios, B. G., Pierce, E. A., & Huckfeldt, R. M. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1887903 · Cited by 13
“of the two halves, as well as the challenges of recombining the two halves in situ.(48) However, recent results with split-gene delivery of MYO7A in vitro and in vivo may offer some ground for optimism.”
ResultRetinal Gene Therapy Using Adeno-Associated Viral Vectors: Multiple Applications for a Small Virus
Hauswirth, W. W. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2530 · Cited by 12
“Such vectors are in development for Myo7a Usher 1D (Dyka et al., 2014; Trapani et al., 2014), ABCA4 recessive Stargardt disease (Trapani et al., 2014), and CEP290 LCA, all RDs with causative cDNAs too large for a single AAV vector.”
BackgroundRecovery kinetics of dual AAV-mediated human otoferlin expression
Sellon, J. B., So, K. S., D'Arcangelo, A., Cancelarich, S., Drummond, M. C., Slade, P. G., Pan, N., Gibson, T. M., Yang, T., Burns, J. C., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1376128 · Cited by 11
“…donor and acceptor sides flanking homologous regions, allow for and efficient recombination in the correct orientation and a high amount of full-length transcript (Ghosh et al., 2008; Dyka et al., 2014; Trapani et al., 2014; McClements and MacLaren, 2017; Reisinger, 2020; Rankovic et al., 2021).”
BackgroundMethodCo-transduction of dual-adeno-associated virus vectors in the neonatal and adult mouse utricles
Chen, Z.-R., Guo, J., He, L., Liu, S., Xu, J.-Y., Yang, Z.-J., Su, W., Liu, K., Gong, S., & Wang, G. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1020803 · Cited by 10
Rekindling Vision: Innovative Strategies for Treating Retinal Degeneration
Khan, I., Ramzan, F., Tayyab, H., & Damji, K. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094078 · Cited by 10
Gene Therapy to Rescue Retinal Degeneration Caused by Mutations in Rhodopsin
Rossmiller, B. P., Ryals, R. C., & Lewin, A. S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2330-4_25 · Cited by 11
Adeno-Associated Viral Gene Therapy for Retinal Disorders
Silva, S. R. D., McClements, M. E., Hankins, M. W., & MacLaren, R. E. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_9 · Cited by 11
Update on Gene Therapy in the Treatment of Hereditary Hearing Loss
He, W., Han, S., Liu, X., Huang, X., Yang, W., Tang, X., Dong, C., & Fan, J. (2025) · Sensory Neuroscience · doi:10.1002/sen2.70004 · Cited by 9
Retinitis Pigmentosa: From Genetic Insights to Innovative Therapeutic Approaches—A Literature Review
Calderón, R. A. M., Emanuelli, A., & Izquierdo, N. (2025) · Medicina · doi:10.3390/medicina61071179 · Cited by 11
“For example, Trapani and co-workers emphasized that approximately one-third of genes implicated in inherited retinal diseases exceed the natural capacity of AAV vectors, presenting an obstacle to therapeutic development [49].”
Toutounchian, S., Ahmadbeigi, N., & Mansouri, V. (2022) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0022 · Cited by 10
“131 Different serotypes of AAV have been identified, but most studies in gene therapy of ocular diseases have been using serotypes AAV2, AAV5, and AAV8.”
Clinical gene therapy restores hearing: a paradigm shift
Han, S., Chen, Z., Wang, D., Jiang, L., Fan, X., Zhong, J., Cui, C., Chen, Y., lv, J., Zhang, J., et al. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.007 · Cited by 8
New CRISPR Tools to Correct Pathogenic Mutations in Usher Syndrome
Major, L., McClements, M. E., & MacLaren, R. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911669 · Cited by 8
“found that dual AAV8 vectors achieved only 6% of the retinal transduction rates found with the single vector [18].”
BackgroundGene therapy proves successful in treating hereditary deafness
Reisinger, E., & Trapani, I. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00496-3 · Cited by 8
Self-citationCurrent approaches for Usher syndrome disease models and developing therapies
Leith, F. K., Lye, J., Delaney, D. S., McLenachan, S., Chen, F. K., Atlas, M. D., & Wong, E. Y. M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1547523 · Cited by 8
AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer’s disease mouse modelPreprint
Rincón, M. Y., Zhou, L., Marneffe, C., Voytyuk, I., Wouters, Y., Dewilde, M., Duqué, S., Vincke, C., Levites, Y., Golde, T., et al. (2019) · bioRxiv · doi:10.1101/698506 · Cited by 6
Potential CRISPR Base Editing Therapeutic Options in a Sorsby Fundus Dystrophy Patient
Elsayed, M. E. A. A., Kaukonen, M. K., Kiraly, P., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2022) · Genes · doi:10.3390/genes13112103 · Cited by 6
“single AAV vector in mice and pigs, respectively [37].”
BackgroundDown-regulation of HuR inhibits pathological angiogenesis in oxygen-induced retinopathy
Huang, X., Liu, Q., Xu, Z.-Y., Yang, X.-H., Xiao, F., Ouyang, P.-W., Yi, W.-Z., zhao, N., Meng, J., Cui, Y., et al. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2022.109378 · Cited by 6
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
“Other multi-AAV approaches have been developed to improve reconstitution efficiency (Tornabene and Trapani 2020) demonstrating early clinical potential, particularly for retinal diseases (Trapani et al. 2014, Trapani 2019).”
Cai, X., Zhang, X., & Bai, H. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/ypgx4 · Cited by 6
Gene therapy shines light on congenital stationary night blindness for future cures
Zhang, Y., Lin, S., Yu, L., Lin, X. Y., Qu, S., Ye, Q., Yu, M., Chen, W., & Wu, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06392-8 · Cited by 5
“After delivery, large gene fragments can be reassembled through trans-splicing, homologous recombination, or a combination of both [156], increasing the AAV capacity to 9 kb.”
Eyes shut homolog (EYS): Connecting molecule to disease
Marques, J. P., Sousa, I. S., Patrício, D., Simões, B. F., Chukwunalu, O., Zeitz, C., Audo, I. S., Collin, R. W. J., Quinn, P. M. J., Ambrósio, A. F., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101391 · Cited by 6
Fehrman, R. L., Chern, K. J., Stoltz, K. P., & Lipinski, D. M. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110223 · Cited by 5
La secuenciación masiva (NGS) como método diagnóstico en la enfermedad de Stargardt
Jimenez‐Rolando, B., Noval, S., Rosa-Pérez, I., Diaz, E. M., del Pozo, Á., Ibáñez, C., Silla-Castro, J. C., Montaño, V. E. F., Martín‐Arenas, R., & Vallespín, E. (2017) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2017.03.012 · Cited by 5
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Metadata
- Authors
- Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., Farrar, G. J., Polishchuk, R., & Auricchio, A.
- Affiliations
- Telethon Institute Of Genetics And Medicine (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Bologna (IT)
- Trinity College Dublin (IE)
- Federico II University Hospital (IT)
- Corresponding author
- Auricchio, Alberto
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-12-16
- Volume
- 6
- Issue
- 2
- Pages
- 194-211
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3927955
- OpenAlex
- W2137826201
- Cited by
- 269
- References
- 82
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 17 · 2023: 24 · 2022: 18 · 2021: 24 · 2020: 31 · 2019: 22 · 2018: 22 · 2017: 23 · 2016: 9 · 2015: 17 · 2014: 13 · 2013: 1
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- European Research Council/ERC (282085)
- European Community's Seventh Framework Programme (242013)
- NIH (R24 RY019861‐01A)
- Italian Telethon Foundation (TGM11MT1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, retinal gene therapy, trans-splicing, homologous recombination, hybrid vectors, Stargardt disease, photoreceptors, inherited retinal disease
- MeSH terms
- Stargardt Disease, Myosin VIIa, Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Injections, Lipofuscin, Macular Degeneration, Mice, Inbred C57BL, Myosins, Phenotype, Retina, Rhodopsin, Transduction, Genetic, Gene Transfer Techniques, ATP-Binding Cassette Transporters, Trans-Splicing, Photoreceptor Cells, Vertebrate, Melanosomes, Sus scrofa, Mice, Usher Syndromes, Retinal Pigment Epithelium, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.